Marinomed Biotech AG (MARI.VI)
EUR 12.2
(-6.15%)
EUR 12.2
(-6.15%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 19.2 Million EUR | 32.91% |
| 2022 | 14.45 Million EUR | 44.58% |
| 2021 | 9.99 Million EUR | 177.13% |
| 2020 | 3.6 Million EUR | 148.88% |
| 2019 | -7.37 Million EUR | -183.02% |
| 2018 | 8.88 Million EUR | 87.46% |
| 2017 | 4.74 Million EUR | 20.98% |
| 2016 | 3.91 Million EUR | 200.23% |
| 2015 | 1.3 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 19.88 Million EUR | 3.55% |
| 2023 Q4 | 19.2 Million EUR | 3.24% |
| 2023 Q2 | 16.15 Million EUR | 8.61% |
| 2023 Q3 | 18.6 Million EUR | 15.18% |
| 2023 Q1 | 14.87 Million EUR | 2.91% |
| 2023 FY | 19.2 Million EUR | 32.91% |
| 2022 FY | 14.45 Million EUR | 44.58% |
| 2022 Q4 | 14.45 Million EUR | 7.0% |
| 2022 Q3 | 13.5 Million EUR | 15.97% |
| 2022 Q2 | 11.64 Million EUR | 9.91% |
| 2022 Q1 | 10.59 Million EUR | 6.0% |
| 2021 FY | 9.99 Million EUR | 177.13% |
| 2021 Q2 | 9.8 Million EUR | 22.43% |
| 2021 Q4 | 9.99 Million EUR | 0.41% |
| 2021 Q3 | 9.95 Million EUR | 1.58% |
| 2021 Q1 | 8 Million EUR | 121.92% |
| 2020 Q3 | -286 Thousand EUR | 90.49% |
| 2020 Q2 | -3 Million EUR | 44.9% |
| 2020 Q1 | -5.45 Million EUR | 26.02% |
| 2020 FY | 3.6 Million EUR | 148.88% |
| 2020 Q4 | 3.6 Million EUR | 1361.22% |
| 2019 FY | -7.37 Million EUR | -183.02% |
| 2019 Q4 | -7.37 Million EUR | 24.28% |
| 2019 Q3 | -9.74 Million EUR | 18.62% |
| 2019 Q2 | -11.97 Million EUR | 16.54% |
| 2019 Q1 | -14.34 Million EUR | -261.43% |
| 2018 Q4 | 8.88 Million EUR | 23.15% |
| 2018 FY | 8.88 Million EUR | 87.46% |
| 2018 Q3 | 7.21 Million EUR | 0.0% |
| 2017 Q4 | 4.74 Million EUR | 0.0% |
| 2017 FY | 4.74 Million EUR | 20.98% |
| 2016 FY | 3.91 Million EUR | 200.23% |
| 2015 FY | 1.3 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|